Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery | News
Search Refinements

Drug Delivery News

View news from other Pharmaceutical sectors:
31-45 of 2298 results
RaNA Therapeutics acquires Messenger RNA Platform from Shire
RaNA Therapeutics has acquired the MRT platform, an mRNA therapy platform, developed by subsidiaries of Shire.
Drug Research > Drug Delivery > News
Cannabics Pharmaceuticals unveils new dosage of 5mg THC Cannabis capsule
Cannabics Pharmaceuticals has unveiled a new dosage of 5mg THC Cannabis capsule to treat cancer patients suffering from Cachexia and Anorexia Syndrome.
Drug Research > Drug Delivery > News
Factor One Source Pharmacy to buy Fast Access Specialty Therapeutics
Factor One Source Pharmacy (FOSRx) has agreed to acquire Fast Access Specialty Therapeutics (F.A.S.T.) for a combination of cash and stock.
Drug Research > Drug Delivery > News
TetraLogic sells SMAC Mimetic and HDAC Inhibitor assets to Medivir
TetraLogic Pharmaceuticals has completed the sale of its SMAC Mimetic and HDAC Inhibitor assets to Medivir.
Drug Research > Drug Delivery > News
Clinigen to distribute BioQ Pharma’s pain relief drug in Europe
Clinigen Group’s Idis Global Access (GA) division has signed a supply and distribution agreement with ready-to-use infusible products developer BioQ Pharma.
Drug Research > Drug Delivery > News
Baxter to acquire Claris Injectables for $625m
By PBR Staff Writer
US drug maker Baxter International has agreed to acquire Claris Lifesciences' injectables business for about $625m.
Drug Research > Drug Delivery > News
Proton Partners to build new cancer center in Reading, UK
Proton Partners International has secured formal planning permission to establish a new cancer treatment center in Reading, Berkshire, UK.
Drug Research > Drug Delivery > News
Cardiome Pharma launches Xydalba (dalbavancin) in UK
Cardiome Pharma has launched XYDALBA for injection, a second-generation, semi-synthetic lipoglycopeptide, in the UK earlier than expected.
Drug Research > Drug Delivery > News
Endo returns rights for BELBUCA to BioDelivery Sciences International
Endo International has entered into an agreement with its partner, BioDelivery Sciences International (BDSI), to return the BELBUCA (buprenorphine) buccal film product to BDSI.
Drug Research > Drug Delivery > News
GlobalData says NSCLC market will increase to $26.71bn by 2025
Research and consulting firm GlobalData said the non-small cell lung cancer (NSCLC) market across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, the UK, Japan, and China, is set to increase to $26.71bn by 2025 from $6.21bn in 2015, representing a very strong compound annual growth rate of 15.7%.
Drug Research > Drug Delivery > News
FDA approves DARZALEX for relapsed multiple myeloma
Genmab has secured approval from the US Food and Drug Administration (FDA) to use DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Drug Research > Drug Delivery > News
Immune Pharmaceuticals secures up to $11m in new financing
Immune Pharmaceuticals has secured up to $11m in new financing, which will be deployed with a focus on bertilimumab clinical development.
Drug Research > Drug Delivery > News
Albireo’s lead product candidate for PFIC accepted into EMA's PRIME Program
Albireo Pharma's lead product candidate, A4250, has been granted access to the PRIority MEdicines (PRIME) program of the European Medicines Agency (EMA) to treat progressive familial intrahepatic cholestasis (PFIC).
Drug Research > Drug Delivery > News
Midatech Pharma selects MTR104 candidate for liver cancer treatment
Midatech Pharma has selected its wholly-owned candidate compound, MTR104, to take into a formal IND-enabling programme during 2017, followed by human studies planned for 2018.
Drug Research > Drug Delivery > News
Pfizer’s Celebrex found to be no riskier for hearts than other rival pain drugs
By PBR Staff Writer
A new study has found that Pfizer’s arthritis drug Celebrex (celecoxib) posed no higher risk to a patient’s heart when compared to its rivals, Ibuprofen and Naproxen.
Drug Research > Drug Delivery > News
31-45 of 2298 results